

Appl. No. 10/771,259

AMENDMENTS TO THE CLAIMS

1. Cancelled

2. (Currently Amended) A pharmaceutical composition for topical administration to treat recurrent herpes infections consisting essentially of a synergistic combination of an active topically acceptable antiviral ingredient substance selected from the group consisting of ~~foscarnet~~, acyclovir, ~~cidofovir~~, ~~deseiclovir~~, ~~fameiclovir~~, ~~ganciclovir~~, ~~lobucavir~~, ~~penciclovir~~, ~~PMEA~~, ~~valacyclovir~~, ~~2242~~, ~~PAA~~, ~~PFA~~ and 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) or an ester, salt or solvate thereof and an active anti-inflammatory glucocorticoid ingredient selected from the group consisting of ~~alelometasone~~, ~~amcinonide~~, ~~beclomethasone~~, ~~budesonide~~, ~~ciclesonide~~, ~~clobetasone~~, ~~clocortolone~~, ~~cloprednol~~, ~~cortison~~, ~~desonide~~, ~~desoximethasone~~, ~~dexamethasone~~, ~~diflurosane~~, ~~diflucortolone~~, ~~difluprednate~~, ~~fludrocortisone~~, ~~fludroxcortid~~, ~~flumethasone~~, ~~flunisolide~~, ~~fluciclonolone acetoneide~~, ~~fluocinonide~~, ~~fluocortin~~, ~~fluocortolone~~, ~~fluprednidene~~, ~~fluticasone~~, ~~halcinonide~~, ~~halobetasol~~, ~~halometasone~~, ~~hydrocortisone~~, ~~methylprednisolone~~, ~~memetasone~~, ~~paramethasone~~, ~~prednisolone~~, ~~prednicarbate~~, ~~prednisone~~, ~~prednylidene~~, ~~refleponide~~, ~~tiredane~~ and ~~triamcinolone~~ and their esters thereof, salts and solvates in a pharmaceutically acceptable carrier, wherein said synergistic combination of antiviral and glucocorticoid is more effective than either component alone.

3. Cancelled

4. (Currently Amended) The pharmaceutical composition according to claim 2, wherein the anti-inflammatory glucocorticoid is selected from the group consisting of ~~hydrocortisone~~, ~~alelometasone~~, ~~desonide~~, ~~fluprednidene~~, ~~flumethasone~~, ~~hydrocortisone butyrate~~, ~~clobetasone~~, ~~triamcinolone acetoneide~~, ~~betamethasone~~, ~~budesonide~~, ~~desoximethasone~~, ~~diflurosane~~, ~~fluciclonolone~~, ~~fluocortolone~~, ~~fluticasone~~, ~~methylprednisolone aceponate~~, ~~memetasone~~ and ~~refleponide~~ or an ester, salt or solvate thereof.

Appl. No. 10/771,259

5. (Currently Amended) The pharmaceutical composition according to claim 2, wherein the anti-viral ~~substance~~ is foscarnet and the anti-inflammatory glucocorticoid is hydrocortisone, ~~or an ester thereof~~.

6. Cancelled

7. (Currently Amended) ~~The A~~ pharmaceutical composition according to claim 2, wherein the antiviral ~~substance~~ is acyclovir, ~~or an ester, salt or solvate thereof~~, and the anti-inflammatory glucocorticoid is hydrocortisone, ~~or an ester thereof~~.

8. (Currently Amended) The pharmaceutical composition according to claim 5 ~~comprising wherein said foscarnet is contained in an amount of 0.1-10% (w/w) foscarnet and said hydrocortisone is contained in an amount of 0.005-3% (w/w) hydrocortisone.~~

9. (Currently Amended) The pharmaceutical composition according to claim 8 ~~comprising wherein said foscarnet is contained in an amount of 1-5% (w/w) foscarnet.~~

10. (Currently Amended) The pharmaceutical composition according to claim 8 ~~comprising wherein said foscarnet is contained in an amount of 0.3-3% (w/w) foscarnet and said hydrocortisone is contained in an amount of 0.25-1% (w/w) hydrocortisone.~~

11. Cancelled

12. Cancelled

13. (Currently Amended) The pharmaceutical composition according to claim 7 ~~comprising wherein said acyclovir is contained in an amount of 0.1-10% (w/w) acyclovir and said hydrocortisone is contained in an amount of 0.005-3% (w/w) hydrocortisone.~~

Appl. No. 10/771,259

14. (Currently Amended) The pharmaceutical composition according to claim 13 comprising wherein said acyclovir is contained in an amount of 1-5% (w/w) acyclovir.
15. (Currently Amended) The pharmaceutical composition according to claim 14 comprising wherein said hydrocortisone is contained in an amount of 0.25-1% (w/w) hydrocortisone.
16. (Currently Amended) A cream, lotion, gel, ointment, plaster, stick or pen containing a pharmaceutical composition according to any one of claims 2, 4, 5, 7-10 and 13-15.
17. Cancelled
18. (Currently Amended) A method for treating recurrent herpes virus infections of the skin or mucous membranes in mammals having or identified as being at risk of developing said infections comprising topically administering thereto, in combination or in sequence, a therapeutically synergistic dose of an active ~~topically acceptable~~ antiviral substance ingredient selected from the group consisting of foscarnet, acyclovir, eidofovir, desciclovir, famciclovir, ganciclovir, lebecavir, penciclovir, PMEA, valacyclovir, 2242, PAA, PFA and 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) or an ester, salt or solvate thereof and an active anti-inflammatory glucocorticoid ingredient selected from the group consisting of alelometasone, amcinonide, beclomethasone, budesonide, ciclesonide, clobetasone, clocortolone, clocortolone, clocortolone, cortison, desonide, desoximethasone, dexamethasone, diflurosane, diflucortolone, difluprednate, fludrocortisone, fludrocortid, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin, fluocortolone, fluprednidene, fluticasone, halcinonide, halobetasol, halometasone, hydrocortisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednicarbate, prednisone, prednylidene, roflepenide, tipredane and triamcinolone and their esters thereof, salts and solvates in a pharmaceutically acceptable carrier, wherein said synergistic dose of antiviral and glucocorticoid is more effective than either component used alone.

Appl. No. 10/771,259

19. Cancelled

20. (Currently Amended) The method according to claim 18, wherein the anti-inflammatory glucocorticoid is selected from the group consisting of hydrocortisone, ~~alelometasone, desonide, fluprednidene, flumethasone, hydrocortisone butyrate, elebetasone, triamcinolone acetonide, betamethasone, budesonide, desoximethasone, diflurosane, flucinolone, flucortolone, fluticasone, methylprednisolone acetonate, mometasone and rofleponide or an ester, salt or solvate thereof.~~

21. (Previously Presented) The method according to claim 18, wherein the antiviral substance is foscarnet and the anti-inflammatory glucocorticoid is hydrocortisone, or an ester thereof.

22. Cancelled

23. (Currently Amended) A method according to claim 18, wherein the antiviral substance is acyclovir, or an ester, salt or solvate thereof, and the anti-inflammatory glucocorticoid is hydrocortisone, or an ester thereof.

24. (Currently Amended) A method for treating recurrent herpes virus infections of the skin or mucous membranes in mammals having or identified as being at risk of developing said infections comprising topically administering thereto a therapeutic dose of a topically acceptable composition according to any one of claims 2, 4, 5, 7-10 and 13-15.

25. (Previously Presented) The method according to claim 24 wherein the composition is contained in a cream, lotion, gel, ointment, plaster, stick or pen.

26. Cancelled

Appl. No. 10/771,259

27. (Currently Amended) A method according to any one of claims 18, 20, 21 and ~~20-23~~, wherein the antiviral substance and the glucocorticoid are administered 1 to 10 times per day.
28. (Previously Presented) The method according to claim 27, wherein the antiviral substance and the glucocorticoid are administered 3 to 4 times per day.
29. (Currently Amended) The method according to claim 4026, wherein the antiviral substance and the glucocorticoid are administered 1 to 10 times per day.
30. (Previously Presented) The method according to claim 29, wherein the antiviral substance and the glucocorticoid are administered 3 to 4 times per day.
31. (Currently Amended) A method according to any one of claims 18, 20, 21 and ~~20-23~~ wherein the antiviral substance and the glucocorticoid are administered in combination and are contained in a cream, lotion, gel, ointment, plaster, stick or pen.
32. Cancelled
33. (Previously Presented) The method according to claim 24, wherein the antiviral substance and the glucocorticoid are administered 1 to 10 times per day.
34. (Previously Presented) The method according to claim 33, wherein the antiviral substance and the glucocorticoid are administered 3 to 4 times per day.
35. (Previously Presented) The method according to claim 31, wherein the antiviral substance and the glucocorticoid are administered 1 to 10 times per day.
36. (Previously Presented) The method according to claim 35, wherein the antiviral substance and the glucocorticoid are administered 3 to 4 times per day.

Appl. No. 10/771,259

37. Cancelled

38. Cancelled

39. Cancelled

40. (Previously Presented) The method according to claim 18, wherein said antiviral is acyclovir and said anti-inflammatory glucocorticoid is hydrocortisone, ~~or an ester thereof.~~

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**